ARTICLE | Company News
Affomix, KalGene deal
January 11, 2010 8:00 AM UTC
Affomix will use its Y2HExpress technology to generate antibodies against undisclosed targets from Kalgene for potential diagnostic and therapeutic use in breast cancer. Affomix will receive an upfron...